Found "Vaccines": 76 results
What criteria do decision makers in Thailand use to set priorities for vaccine introduction? (2016)
Siriporn Pooripussarakul1, Arthorn Riewpaiboon1* , David Bishai2, Charung Muangchana3 and Sripen Tantivess4
Abstract
Background: There is a need to identify rational criteria and set priorities for vaccines. In Thailand, many licensed vaccines are being considering for introduction into the Ex
What the Role of HTA in Healthcare Systems should be after COVID-19?
The COVID-19 pandemic has transformed healthcare systems around the world. One of important issues that COVID-19 clearly emphasizes is the critical importance of information on health technology and policy. Handling the COVID-19 pandemic was difficult at the beginning because humanity all faced the
WORKSHOP ON VACCINE ECONOMICS AND FOLLOW-UP ON HTA STUDIES
The International Decision Support Initiative (iDSI) lead by Health Intervention Technology Assessment Program (HITAP) has been working closely with the Health Technology Assessment Committee (HTAC) the nodal agency responsible for health technology assessment (HTA) under the Ministry of Health, Ind
Would a rotavirus vaccination program for children under 5 years be cost-effective for Bhutan?
In many countries, rotavirus vaccination is the most cost-effective way to prevent rotavirus diarrhea. With this in mind, the Essential Medicines and Technology Division (EMTD) in collaboration with Health Intervention Technology Assessment Program (HITAP), Mahidol Oxford Research Unit (MORU), and P
[Press Release] 5 Leading Agencies Join Forces to Promote Early Health Technology Assessment for Development of Medical and Healthcare Innovations in Thailand
On June 19, 2023, the Health Intervention and Technology Assessment Program Foundation (HITAP Foundation), in collaboration with the Saw Swee Hock School of Public Health of the National University of Singapore (NUS), organized a workshop on “Fruitful Research: How to Make Health Innovation Worthwhi
การวิเคราะห์ต้นทุนระบบเฝ้าระวังในโรคป้องกันด้วยวัคซีน (หัดและหัดเยอรมัน) และต้นทุนส่วนเพิ่มเพื่อการกำจัดโรคหัดและหัดเยอรมันในประเทศไทย
Department of Immunization, Vaccines and Biologicals, World Health Organization (WHO) ได้รับการสนับสนุนเงินทุนจาก Global Alliance for Vaccines and Immunization (GAVI) และ the Centers for Disease Control and Prevention (US CDC) เพื่อริเริ่มโครงการพั
10 / Page